Physician profile
Michael Rie
NPI 1902009301
$10,548.78
in general payments reported to CMS, 2019-2025
47 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,362 · 2020: $1,814 · 2021: $1,712 · 2022: $2,389 · 2023: $2,251 · 2024: $20.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,271.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,712.45 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,000.87 | 2019-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $824.51 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Abbvie INC. | $802.88 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $637.24 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $624.54 | 2019-2023 | Synjardy, Jardiance |
| Gilead Sciences, INC. | $511.21 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $496.48 | 2019-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $471.29 | 2019-2023 | Xifaxan |
| Jazz Pharmaceuticals INC. | $365.78 | 2022-2023 | Rylaze |
| Pfizer INC. | $352.95 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $299.22 | 2022-2023 | |
| Amarin Pharma, INC. | $221.61 | 2019-2022 | |
| Astellas Pharma US INC | $220.30 | 2019-2023 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $212.02 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.